Hepatocellular Carcinoma
Preclinical rationale for apigenin in hepatocellular carcinoma, including pathway effects and sensitisation data.
Why this cancer is a plausible fit
Hepatocellular carcinoma has limited treatment options beyond agents such as sorafenib and lenvatinib. Apigenin’s effects on PI3K/AKT, NF-κB, tumour microenvironment signalling, and drug sensitisation make it biologically coherent in this setting.
The animal literature is among the most supportive across all cancer types reviewed.
Cell data
Multiple hepatocellular carcinoma cell lines have been studied, including HepG2, Huh-7, Hep3B, and SNU-449.
Reported effects include:
inhibition of proliferation and induction of apoptosis or autophagy in
HepG2andHuh-7suppression of
PI3K/AKTsignalling, with cell-cycle disruption and apoptosisenhancement of doxorubicin and sorafenib activity in cell models
increased
Hep3Bcell death through the mitochondrial apoptosis pathway
One study found that direct antiproliferative effects on SNU-449 cells were relatively modest, suggesting tumour-microenvironment modulation may be the more relevant mechanism in some subtypes. That nuance matters.
Animal data
Animal studies show:
significant inhibition of tumour growth alongside recovery of doxorubicin and sorafenib activity
anti-metastatic effects with reduced metastatic nodule counts
hepatoprotective effects against chemical liver injury in several models, raising the possibility of concurrent liver-tissue protection during treatment
Human data
No human hepatocellular carcinoma outcome data exist.
Some hepatoprotective dietary epidemiology exists, but it is not cancer-specific.
Clinical positioning
This is an early but important area.
The sorafenib sensitisation data are especially relevant because sorafenib resistance is a common clinical problem in hepatocellular carcinoma. No human cancer data exist.